节点文献

参芪扶正注射液联合化疗治疗急性非淋巴细胞白血病的临床研究

Clinical Study of Shenqifuzheng injection and Chemotherapy in DA Protocol in Treating Acute Nonlymphocytic Leukemia

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 吴东红杨志刚李庆华

【Author】 WU Dong-hong,YANG Zhi-gang,LI Qing-hua(Departement of Hematology,The Affiliated Hospital of Guangdong Medical College;Zhanjiang 524001;China)

【机构】 广东医学院附属医院血液内科

【摘要】 目的比较参芪扶正注射液联合DA化疗方案或单纯DA方案治疗急性非淋巴细胞白血病(ANLL)的疗效及不良反应。方法入选的60例ANLL患者分为两组,观察组32例,采用参芪扶正注射液联合DA化疗方案治疗;对照组28例,单纯用DA方案治疗。观察两组缓解率、临床症状、不良反应等指标。结果观察组CR率为71.86%,明显高于对照组的53.57%(P<0.05);观察组总有效率(CR+PR)为93.72%明显高于对照组的71.43%(P<0.01)。两组临床症状改善率分别为75.00%和53.57%,两组比较有显著差异(P<0.05)。观察组神经毒性及心脏毒性的发生率明显低于对照组(P<0.01)。结论参芪扶正注射液联合DA化疗方案治疗急性非淋巴细胞白血病可起到减轻化疗的不良反应,提高治疗效果的作用。

【Abstract】 Objective To compare the efficacy and adverse reaction of chemotherapy in DA protocol alone or combined with Shenqifuzheng injection(SFI) for treatment of acute nonlymphocytic leukemia.Methods 60 patients were divided into 2 groups,the observed group(n=32)treated with DA plus SFI.And the control group(n=28)treated with DA alone.The remission rate,clinical symptom and adverse reaction of two groups were observed.Results In the treated group,CR rate was 71.86%,total effective rate was 93.72%;while in the control group,CR rate was 53.57%,total effective rate was 71.43%.Patients’ improvement rate of clinical symptom in the treated group was improved more obviously than that in the control group(P<0.05),and the incidence rate of adverse reaction as neurotoxicity and cardiac toxicity were lower in the treated group than those in the control group(P<0.01).Conclusion Shenqifuzheng injection combined with DA protocol on acute nonlymphocytic leukemia can reduce the adverse reaction of chemotherapy and improve the therapeutic efficacy.

  • 【文献出处】 中国医疗前沿 ,China Healthcare Frontiers , 编辑部邮箱 ,2009年05期
  • 【分类号】R733.71
  • 【被引频次】2
  • 【下载频次】106
节点文献中: 

本文链接的文献网络图示:

本文的引文网络